119th Congress · introduced in the House · Feb 12, 2025
Mikaela Naylon Give Kids a Chance Act
Official title from Congress.gov
Latest action (Dec 2, 2025): Received in the Senate.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Feb 12, 2025)
Give Kids a Chance Act of 2025
This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research.
Specifically, the bill
• modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met;
• permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement;
• renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and
Show the full summary (2 more paragraphs)Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Received in the Senate.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4929-4932)
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4929-4932)
DEBATE - The House proceeded with forty minutes of debate on H.R. 1262.
Considered under suspension of the rules. (consideration: CR H4929-4935)
Mr. Carter (GA) moved to suspend the rules and pass the bill, as amended.
Placed on the Union Calendar, Calendar No. 304.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-352.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-352.
Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 47 - 0.
Committee Consideration and Mark-up Session Held
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Arab-Israeli relations · Bahrain · Cancer · Child health · Computers and information technology · Congressional oversight · Drug safety, medical device, and laboratory regulation · Executive agency funding and structure · Food and Drug Administration (FDA) · Government information and archives · Government studies and investigations · Health information and medical records · International law and treaties · Israel · Licensing and registrations · Medical research · Organ and tissue donation and transplantation · Performance measurement · Prescription drugs · Research administration and funding · Telephone and wireless communication · United Arab Emirates · User charges and fees
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
283 citations; showing the 25 most recently posted.
NATIONWIDE CHILDREN'S HOSPITAL INC · lobbying firm or registrant: NATIONWIDE CHILDREN'S HOSPITAL, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$57,000
Spent on own lobbying
…302 Healthy Start Reauthorization Act of 2025 H.R.5371 Continuing Appropriations and Extensions Act of 2026 S. 3389 Lowering Health care Cost for Americans Act H.R. 1262 Mikaela Naylon Give Kids a Chance Act H.R. 5582 Patients Deserve Price Tags Act H.R. 5304 Departments of Labor, Health and Human Services, and Education, and R…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONWIDE CHILDREN'S HOSPITAL INC · lobbying firm or registrant: NATIONWIDE CHILDREN'S HOSPITAL, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Medicare/Medicaid
$57,000
Spent on own lobbying
…302 Healthy Start Reauthorization Act of 2025 H.R.5371 Continuing Appropriations and Extensions Act of 2026 S. 3389 Lowering Health care Cost for Americans Act H.R. 1262 Mikaela Naylon Give Kids a Chance Act H.R. 5582 Patients Deserve Price Tags Act H.R. 5304 Departments of Labor, Health and Human Services, and Education, and R…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.) · lobbying firm or registrant: NATIONAL ASSOCIATION OF CHILDRENS HOSPITALS AND AFFILIATES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$1,520,000
Spent on own lobbying
…al Health Infrastructure Act Issues related Pub. L No. 119-21; specifically state direct payments. H.R. 3890, Resident Physician Shortage Reduction Act of 2025 H.R. 1262/S.932, Give Kids a Chance Act H.R. 3505, Barriers to Suicide Act H.R. 4262, To reauthorize programs related to health professions education, and for other purp…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.) · lobbying firm or registrant: NATIONAL ASSOCIATION OF CHILDRENS HOSPITALS AND AFFILIATES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$1,520,000
Spent on own lobbying
…g Medicaid supplemental payments and directed payments. Issues regarding out of state care for children enrolled in Medicaid. Issues regarding Hospital at Home H.R. 1262/S.932 Give Kids a Chance Act H.R. 1509/S. 752 Accelerating Kids Access to Care Act Issues related Pub. L No. 119-21; specifically state directed payments.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DANA-FARBER CANCER INSTITUTE · lobbying firm or registrant: DANA-FARBER CANCER INSTITUTE
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$19,219
Spent on own lobbying
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DANA-FARBER CANCER INSTITUTE · lobbying firm or registrant: DANA-FARBER CANCER INSTITUTE
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medical/Disease Research/Clinical Labs
$19,219
Spent on own lobbying
…to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOGEN · lobbying firm or registrant: BIOGEN
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$880,000
Spent on own lobbying
…ker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE CAMPAIGN FOR SUSTAINABLE RX PRICING · lobbying firm or registrant: MEHLMAN CONSULTING, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$90,000
Paid to lobbying firm
…5526 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 2630 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R.1262 - Mikaela Naylon Give Kids a Chance Act. S. 3014 - Ensuring Timely Access to Generics Act of 2025 S. 1414 - Expedited Access to Biosimilars Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ACADIA PHARMACEUTICALS · lobbying firm or registrant: ACADIA PHARMACEUTICALS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$440,000
Spent on own lobbying
Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 193…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TRAVERE THERAPEUTICS · lobbying firm or registrant: TRAVERE THERAPEUTICS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medical/Disease Research/Clinical Labs
$100,000
Spent on own lobbying
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reautho…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PTC THERAPEUTICS, INC. · lobbying firm or registrant: LMH STRATEGIC SOLUTIONS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$50,000
Paid to lobbying firm
…Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
IONIS PHARMACEUTICALS, INC. · lobbying firm or registrant: LMH STRATEGIC SOLUTIONS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$30,000
Paid to lobbying firm
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTCT · lobbying firm or registrant: SMITHBUCKLIN CORPORATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Health Issues
$70,000
Paid to lobbying firm
…orm Guidance Oversight H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160/S.4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act S. 4440/H.R. 3521 - The Clinical Trial Modernization Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
IONIS PHARMACEUTICALS, INC. · lobbying firm or registrant: IONIS PHARMACEUTICALS, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Health Issues
$150,000
Spent on own lobbying
Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025. Issues related to drug pricing policy.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL BRAIN TUMOR SOCIETY · lobbying firm or registrant: BRACEWELL LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Health Issues
$20,000
Paid to lobbying firm
Issues related to the Bolstering Research And Innovation Now (BRAIN) Act (H.R.2767/S.1330), Mikaela Naylon Give Kids a Chance Act (H.R.1262)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BAYER CORPORATION (CONSOLIDATED REPORT) · lobbying firm or registrant: BAYER CORPORATION (CONSOLIDATED REPORT)
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · amended · posted Aug 31, 2026 · issue area: Health Issues
$2,040,000
Spent on own lobbying
…rica Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. H.R. 1262, Give Kids a Chance Act of 2025. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. S. 932, Give Kids a Chance Act of 2025. S. 3677, Dietary Supplement L…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BAYER CORPORATION (CONSOLIDATED REPORT) · lobbying firm or registrant: BAYER CORPORATION (CONSOLIDATED REPORT)
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · amended · posted Aug 31, 2026 · issue area: Health Issues
$1,760,000
Spent on own lobbying
…ion related to DEA-determined pseudoephedrine quotas. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). H.R. 1262, Give Kids a Chance Act of 2025. S. 932, Give Kids a Chance Act of 2025.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · lobbying firm or registrant: WHITMER & WORRALL, LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 22, 2026 · issue area: Pharmacy
$50,000
Paid to lobbying firm
…1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
FORTRESS BIOTECH INC. · lobbying firm or registrant: THE VOGEL GROUP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Health Issues
Amount not reported
Give kids a chance act H.R.1262; issues related to rare pediatric disease and priority review vouchers
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. View filing
BIOGEN · lobbying firm or registrant: BIOGEN
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$1,060,000
Spent on own lobbying
…and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, dete…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
STEALTH BIOTHERAPEUTICS INC. · lobbying firm or registrant: STEALTH BIOTHERAPEUTICS INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$120,000
Spent on own lobbying
H.R. 1262/S. 932 - Mikaela Naylon Give Kids a Chance Act General discussions about ultra-rare diseases General discussions about ultra-rare disease drug development Gene…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.) · lobbying firm or registrant: NATIONAL ASSOCIATION OF CHILDRENS HOSPITALS AND AFFILIATES
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$1,370,000
Spent on own lobbying
…al Health Infrastructure Act Issues related Pub. L No. 119-21; specifically state direct payments. H.R. 3890, Resident Physician Shortage Reduction Act of 2025 H.R. 1262/S.932, Give Kids a Chance Act H.R. 3505, Barriers to Suicide Act H.R. 4262, To reauthorize programs related to health professions education, and for other purp…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.) · lobbying firm or registrant: NATIONAL ASSOCIATION OF CHILDRENS HOSPITALS AND AFFILIATES
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$1,370,000
Spent on own lobbying
…rtionate Share Hospitals (DSH) and directed payments. Issues regarding out of state care for children enrolled in Medicaid. Issues related to Hospital at Home. H.R. 1262/S.932 Give Kids a Chance Act H.R. 1509/S. 752 Accelerating Kids Access to Care Act Issues related Pub. L No. 119-21; specifically state directed payments.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · lobbying firm or registrant: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$7,360,000
Spent on own lobbying
…3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and bi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DANA-FARBER CANCER INSTITUTE · lobbying firm or registrant: DANA-FARBER CANCER INSTITUTE
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$36,000
Spent on own lobbying
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing